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Abstract
Reactive arthritis (ReA), also known as sterile postin-
fectious arthritis, belongs to the group of related ar-
thropathies known as spondyloarthritis (SpA). ReA can 
arise 1-4 wk after a gastrointestinal or genitourinary 
infection, but once arthritis develops, the microorgan-
ism is not found in the joint. The classical microbes as-
sociated with ReA development include Gram-negative 
aerobic or microaerophilic bacteria containing LPS in 
their outer membrane. The immunopathogenic mecha-
nisms involved in ReA development are still unknown. 
A hypothesis suggested that the bacteria probably 
persist outside the joint, at sites such as gut mucosa 
or lymph nodes, and bacterial antigens might then be 
transported to the joints. On the other hand, an altered 
immune response and the unbalanced production of cy-
tokines have been reported in subjects with ReA. Cur-
rently, there is increased evidence to suggest that both 
mechanisms would operate in the immunopathogenesis 
of ReA. In this review we highlight recent advances on 
the role of cytokines in the ReA. Particularly, we discuss 
the roles of some pro- and anti-inflammatory cytokines 
involved in the immunopathogenesis of ReA.
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Core tip: The immunopathogenic mechanisms involved 
in reactive arthritis (ReA) development are still un-
known. However, in the last years, increased evidence 
suggests that the immune response in particular cer-
tain cytokines could be involved in the pathogenesis of 
ReA. Currently, the use of biological agents that block 
the action of certain cytokines has contributed to im-
proving the treatment of some rheumatic pathology. 
Understanding the role of cytokines in the pathogenesis 
of ReA could contribute to the development of future 
treatments. In this review, we highlight recent advanc-
es on the role of certain cytokines in the pathogenesis 
of ReA. 
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INTRODUCTION
Reactive arthritis (ReA), also known as sterile postinfec-
tious arthritis, belongs to the group of  related arthropa-
thies known as spondyloarthritis (SpA)[1]. This group 
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also includes undifferentiated SpA, psoriatic arthritis 
(PsA), arthritis associated with inflammatory bowel dis-
ease and ankylosing spondylitis (AS). The SpA arthropa-
thies have common several epidemiological, pathologi-
cal, clinical and radiological features. ReA, as with other 
SpA, exhibits an absence of  rheumatoid factor and has a 
genetic association with the molecule HLA-B27[1-3]. ReA 
can arise 1-4 wk after a gastrointestinal or genitourinary 
infection, but once arthritis develops, the microorganism 
is not found in the joint[2]. The ReA symptoms were rec-
ognized and studied in 1942 by Bauer and Engelmann, 
who associated these symptoms with those described 
in 1916 by the German physician Hans Reiter. At that 
time, Reiter described the clinical triad: arthritis, non-
gonococcal urethritis and conjunctivitis in a German 
soldier after an episode of  bloody diarrhea. So, Bauer 
and Engelmann coined the term Reiter’s syndrome to 
describe this new pathology[2]. However, most patients 
do not have the complete triad of  symptoms. These 
observations drove Ahvonen to propose the name of  
ReA as the term most adapted to describe the “arthritis 
that happens during or after an infection in another site 
of  the body without evidence of  microorganisms in the 
joint”[4]. Yet, this operational definition of  ReA has led 
to uncertain diagnosis in different clinical settings. Thus, 
several attempts have been made to create classification 
criteria; however, lack of  consensus has led to a failure 
to achieve any universally validated diagnostic criteria. 
Based on discussions at the 4th International Workshop 
on ReA, this term should be used only in patients with 
clinical features of  ReA and in cases where a pathogen 
known to cause ReA is implicated[5].
CLINICAL FEATURES
ReA most commonly affects young adults aged 20 to 
40 years old and is rare in children[6-8]. Both sexes are 
equally affected by ReA after a gastrointestinal infec-
tion, while ReA is more frequent in men when triggered 
by a urogenital tract infection[3]. The presence of  the 
HLA-B27 allele does not seem to be related to the onset 
of  ReA; however, HLA-B27 positive patients have more 
severe arthritis with a tendency to progress to a chronic 
stage and they also have a greater chance of  developing 
extra-articular symptoms. One hypothesis suggests that 
this molecule favors the cross-reaction between antigen 
and host, or it might be itself  a target of  the immune 
response[9].
The symptoms of  ReA typically start between 1 to 
4 wk after the gastrointestinal infection. However, the 
triggering infection could be asymptomatic, such as Chla-
mydia-induced ReA, resulting in underdiagnosis[2]. Clinical 
features of  ReA are characterized by asymmetrical oligo-
arthritis, often in large joints of  the lower extremities or 
in the upper extremities. A mild polyarticular form, par-
ticularly in the small joints, can also occur. Patients can 
have dactylitis. The typical extra-articular manifestations 
are enthesitis, tendinitis and bursitis. ReA share these clin-
ical characteristics and inflammatory back pain with other 
members of  SpA, such as AS and PsA[1]. Other extra-
articular features include eye disease, where conjunctivitis 
is most prevalent, followed by acute anterior uveitis, and 
skin changes, such as erythema nodosum, keratodermia 
blennorrhagica and circinate balanitis[3].
The clinical diagnosis is made based on the clinical 
symptoms. Evidence for infection triggering the arthrop-
athy is most convincing when microbe isolation or anti-
gen detection is successful. In this respect, fecal culture 
of  enteric pathogens associated with ReA or the finding 
of  Chlamydia trachomatis nucleic acids in urine, cervical or 
urethral swabs are secondary criteria used to confirm the 
diagnosis.
Animal models
Animal models of  ReA have complemented studies in 
human materials. However, these animal models are lim-
ited since even when they are developed after bacterial 
infection as in human ReA, in some of  them the route of  
infection was intravenous instead of  oral. Table 1 shows 
animal models of  ReA similar to the human form of  the 
disease[10-17]. We have described an experimental model 
useful for studying the pathogenesis of  Yersinia enterocoliti-
ca (Y. enterocolitica) ReA. In our model, TNFRp55 deficient 
mice develop ReA after oral infection with Y. enterocolitica 
O: 3, the most common serotype associated with human 
ReA. TNFRp55-/- mice exhibited macroscopic signs of  
severe and progressive arthritis with significantly higher 
clinical score compared with wild-type mice from d 14 
to 56 after infection[14]. Extensively, increased scores for 
inflammation and bone/cartilage degradation resulted 
when histopathological changes were analyzed in the 
joints. In these animals, we observed luminal disorga-
nization of  the synovial membrane, which was densely 
infiltrated with various types of  leucocytes, sometimes 
concomitant with follicle formation. The articular carti-
lage and bone were degraded. Proliferation of  synovial 
lining cells was also detected[14,15]. This evidence and the 
data presented in Table 1 indicate ReA development 
in animal models that resemble this disease in humans. 
Nevertheless, the convergence of  these models with hu-
man studies will contribute to understand the pathogenic 
mechanisms of  ReA.
TRIGGERING BACTERIAL AND 
PATHOPHYSIOLOGY
The classical bacteria associated with gastrointestinal ReA 
are Yersinia, Salmonella, Shigella and Campylobacter, while C. 
trachomatis is by far the most common cause of  ReA as-
sociated with genital infection[3,18]. All these pathogens are 
Gram-negative aerobic or microaerophilic bacteria con-
taining LPS in their outer membrane.
The immunopathogenic mechanisms involved in ReA 
development are still unknown. Even when bacterial 
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cultures of  synovial fluids are negative in ReA, bacterial 
antigens have been found in the joints of  patients. In 
Chlamydia-induced ReA, bacterial DNA and RNA have 
been detected in the joint, suggesting that live Chlamydia 
are present[19-21]. Positive reaction of  antibodies specific 
to Salmonella and Yersinia antigens in synovial fluid cells of  
ReA patients suggests the presence of  bacterial antigen in 
the joint[22,23]. Based on these findings, some authors have 
suggested that the bacteria probably persist outside the 
joint at sites such as gut mucosa or lymph nodes, and bac-
terial antigens might then be transported by monocytes 
to the joints[24,25]. On the other hand, an altered immune 
response and the unbalanced production of  cytokines 
have been reported in subjects with ReA[26,27]. This altered 
immune response benefits the bacterial persistence and 
disfavors the elimination of  the antigen by the host.
In this review, we highlight recent advances on the 
role of  cytokines in ReA. Particularly, we discuss the 
roles of  pro- and anti-inflammatory cytokines, especially 
interleukin (IL)-17, IL-12, IL-23, IL-6, tumor necrosis 
factor-α (TNF-α), interferon-γ (IFN-γ) as well as IL-10 
in the pathophysiology of  the ReA. Finally, we discuss 
the latest advances in the treatment of  ReA based on the 
use of  biological agents that neutralize the functions of  
certain cytokines, such as TNF-α or IL-6. 
ROLE OF THE CYTOKINES IN ReA
Conflicting data have been reported on the production 
of  cytokines in ReA patients. CD4+ T cells mediate im-
munity as a balance between different lineages of  T 
helper (Th)-1, Th2, Th3 and Th17 which secrete IFN-γ, 
IL-4, TGF-γ and IL-17, respectively, as the main cytokine 
for each profile. Some studies revealed low levels of  Th1 
cytokines in ReA, especially of  TNF-α but also of  IFN-γ 
in peripheral blood and synovium[28-34]. Since Th1 cells 
secreting IFN-γ and TNF-α have been proposed for bac-
terial clearance, defective Th1 response may contribute to 
bacterial persistence. Other data suggest that a Th2 cyto-
kine profile and Th3 response with expression of  TGF-β 
is common in ReA[32]. Temporal relationships of  these 
different Th1 and Th2 cytokines or blunting of  initial 
cytokine response might also be important in the disease 
manifestations and its maintenance. On the other hand, 
the discovery of  Th17 cells and their importance in the 
pathogenesis of  chronic inflammatory diseases suggested 
that these cells may have a pathogenic role in ReA. How-
ever, the available studies are not large enough to support 
the role of  certain cytokines in the pathogenesis of  ReA. 
NOVEL CYTOKINES IMPLICATED IN 
PATHOGENESIS OF ReA
IL-17
IL-17 is a 15-20-kDa glycoprotein produced by a novel 
subset of  Th cells, termed Th17 cells, and to a lesser 
extent by innate lymphoid cells, including T-cells, innate-
like lymphoid cells, mast cells and neutrophils[35]. Th17 
cells are critical in the pathogenesis of  the arthritis, as 
demonstrated in several animal models[36-38]. Th17 dif-
ferentiation, survival and expansion depend on a variety 
of  cytokines and transcription factors that work in con-
cert to drive the induction of  increased Th17 numbers. 
TGF-β in synergy with IL-6 has been described as the 
central factor involved in generating Th17 cells in mice. It 
has been shown in humans that TGF-β, IL-1β and IL-6, 
combined with IL-21 or IL-23, can induce Th17 differ-
entiation[39]. IL-17 binds to IL-17RA/IL-17RC, which is 
expressed by a variety of  cells, such as monocytes, lym-
phocytes, lymphoid tissue inducer cells, epithelial cells, 
synoviocytes, fibroblasts and keratinocytes[35].
Th17 cell responses and IL-17 expression provide 
protection against bacterial and fungal pathogens through 
production and induction of  inflammatory cytokines 
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Table 1  Animal models of reactive arthritis similar to the human form of the disease





Lewis rats Y. enterocolitica
O:81
iv1 1 wk/6 wk Polyarticular arthritis, erythema ND Hill et al[10] 
DBA/2 and 
BDF1 mice
Y. enterocolitica O:8 
plasmid cured1
iv1 Day 31/3 wk Polyarticular arthritis ND Yong et al[11] 
SHR rats Y. enterocolitica
O:81
iv1 1-4 wk/7-25 wk Polyarticular arthritis, erythema, swelling 
and impaired movement of the joint




Y. enterocolitica O:3 iv1/Oral 1-3 wk/2-8 mo Monoarticular arthritis, swelling redness, 
deformations and conjunctivitis




Y. enterocolitica O:3 ig 2 wk/chronic 
until 8 wk
Polyarticular arthritis, swelling, erythema IL-17 
IFN-γ




BALB/c mice S. enteritides ig 1 wk/ND Synovial inflammation TNF-α
IL-17
Noto Llana et al[16]
Noto Llana et al[17] 
1Different to the human form of the disease. ND: Not determined; iv: Intravenous infection; ig: Intragastric infection; IL: Interleukin; TNF: Tumor necrosis 
factor.
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against many pathogens associated with ReA. Thus, the 
low concentrations of  IL-12 have been linked to the bac-
terial persistence hypothesis and then to the pathogenesis 
of  ReA[28]. On the other hand, data on IL-23 concentra-
tions in synovial fluid or serum of  patients with ReA are 
limited, but high levels of  IL-17 found in synovial fluids 
and sera of  patients with ReA may reflect IL-23 activ-
ity. Moreover, abnormality of  IL-12p40 gene expression 
in humans has been reported and IL-12 deficiency has 
been detected in patients with ReA[51,52]. Yin et al[28] found 
that the balance of  anti-inflammatory cytokines (IL-10) 
and IL-12 in the synovial fluid is also important. This 
may contribute to the decreased clearance of  the bacteria 
or their components from the joint and lead to ReA[28]. 
In relation to these findings, a recent study has shown 
that monocyte-derived macrophages from subjects with 
a history of  ReA show low IL-12 and IL-23 produc-
tion[53]. Conversely, some authors have reported that IL-
12/23p40 levels in synovial fluids of  patients with ReA 
and other SpA are higher compared to synovial fluids of  
patients with osteoarthritis (OA) used as control[41,54]. 
Interestingly, we demonstrated that the p40-deficient 
mice develop acute ReA after oral infection with Y. en-
terocolitica, suggesting that IL-12 or IL-23 could exert a 
protective effect on the development of  ReA[55]. How-
ever, we have observed elevated levels of  p40 in regional 
lymph nodes to joints of  TNFRp55-/- mice with Yersinia-
induced ReA. This effect has been accompanied by high 
levels of  IFN-γ and IL-17 in affected joints[15]. These re-
sults are in accordance with the concept that the IL-12/
IL-23 pathway plays a dual role protecting from infection 
and eliciting tissue damage, and support future study to 
determine whether IL-12/23p40 could be a possible tar-
get for ReA treatment.
IL-6
IL-6 is a pleiotropic cytokine that is involved in numer-
ous biological processes. The pleiotropy and redundancy 
of  IL-6 functions have been identified by characterizing 
a unique receptor system comprising two functional pro-
teins: a receptor specific for IL-6 (IL-6R)[56] and gp130, 
the common signal transducer of  cytokines related to 
IL-6, including the IL-12 family cytokines IL-27 and 
IL-35[57,58]. In the early phase of  infectious inflammation, 
IL-6 is produced by monocytes and macrophages imme-
diately after the stimulation with distinct pathogen-asso-
ciated molecular patterns. In noninfectious inflammation, 
damage-associated molecular patterns from damaged 
or dying cells stimulate monocytes and macrophages to 
produce IL-6. The pathogenic role of  IL-6 in rheumatic 
diseases like rheumatoid arthritis (RA) has been well es-
tablished. The critical role for IL-6 in the pathogenesis 
of  RA is provided by clinical trials, in which tocilizumab, 
a humanized mAb specific for IL-6R, has been shown 
to suppress disease activity and erosive progression in 
patients with RA[59]. In ReA, elevated IL-6 concentra-
tions in the plasma and sera of  the patients has been 
reported[60,61]. Moreover, synovial fluid concentrations of  
and granulopoiesis, or by the recruitment of  neutro-
phils. However, Th17 cells producing IL-17 have been 
suggested as the central effector lineage involved in the 
pathogenicity of  ReA[40]. Thus, it has been shown that 
ReA patients have elevated levels of  IL-17 in synovial 
fluid and that this cytokine contributes to the develop-
ment of  joint inflammation[40,41]. Furthermore, high 
expression of  IL-17 was found in the synovial fluid of  
patients with SpA and an increased number of  circulating 
memory Th17 cells has been recently reported in these 
patients[42,43]. Moreover, in patients with C. trachomatis-
induced ReA, increased percentages of  IL-17-positive 
CD4+ T cells[44] and higher IL-17 concentrations were 
detected in synovial fluid[45]. 
Recent works suggest that Salmonella-induced ReA 
in mice dependent on CD4+ T cells secreting IL-17[17]. 
Interestingly, these authors observed that the expression 
of  IL-17 in the large intestine and in mesenteric lymph 
nodes (MLN) resembles that of  popliteal and inguinal 
lymph nodes (ILN)[17]. Accordingly, previous results 
from our laboratory demonstrated that IL-17 plays a ma-
jor role in Yersinia-induced ReA[15]. Furthermore, we de-
tected a strong correlation among IL-17 levels in MLNs, 
ILNs and joints from TNFRp55-/- mice with arthritis, 
supporting a link between the intestinal mucosa and the 
articular immune response. In addition, we observed 
that neutralization of  IL-17 resulted in the abrogation of  
synovitis[15]. In line with these results, other authors have 
reported recently that modulating intestinal IL-23/IL-17 
expression by consumption of  Lactobacillus casei prior to 
Salmonella infection in mice abolishes intestinal and joint 
inflammation[46]. 
These data in animal models and patients support 
the hypothesis that Th17 cells may be involved in ReA 
pathogenesis. However, there are few reports for under-
standing and elucidating the true role of  IL-17 in the 
pathogenesis of  ReA.
IL-12 and IL-23
IL-12 and IL-23 are heterodimeric cytokines that share 
subunits and have important roles in autoimmunity. These 
IL-12 family cytokines share some biological character-
istics but have functional differences. IL-12 is composed 
of  two covalently linked subunits, IL-12p35 and IL-
12p40, while IL-23 is composed of  two covalently linked 
subunits, IL-23p19, which is distantly related to IL-12p35, 
and the IL-12p40 subunit[47,48]. Furthermore, the recep-
tors of  IL-23 and IL-12 are also heterodimers that share 
the receptor 1 chain and have unique 2 chains[49]. IL-12 is 
released by antigen presenting cells such as dendritic cells 
(DCs) and monocytes/macrophages in response to bac-
terial products and immune signals. Furthermore, IL-12 
is the main stimulator of  IFN-γ production by inducing 
development of  Th1 responses[49,50]. In addition, IL-23 is 
produced by macrophages and activated DCs and plays 
a crucial role in the generation of  the Th17 cells. Since 
IL-12 has the ability to orchestrate the Th1 response, this 
cytokine plays a crucial role in the protective immunity 
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IL-6 were higher in patients with ReA[41]. Interestingly, 
we found that mice TNFRp55-deficient macrophages 
are hyperactivated to secrete common pro-inflammatory 
mediators such as NO and IL-6 following stimulation 
with Yersinia antigens. The higher concentrations of  IL-6 
production detected in stimulated TNFRp55-/- macro-
phages may be associated with our previous in vivo results 
demonstrating the increased susceptibility of  TNFRp55-/- 
mice to Yersinia-induced ReA[14]. Furthermore, higher 
concentrations of  IL-6 were detected in the joints of  
these mice which showed a severe chronic synovitis[15]. 
This data suggests that over-synthesis of  IL-6 may be re-
lated to the development of  ReA.
TNF-α
TNF-α is a cytokine prototype of  a large family of  over 
40, known as TNF superfamily, and TNF receptor (TNFR) 
proteins. TNF-α is a cytokine with pleiotropic functions 
produced by a large number of  cells, but are monocytic 
lineage cells (macrophages, astroglia, microglia, Kupffer 
cells and alveolar macrophages) major sources. Initially, 
this cytokine is produced as a pro-TNF and is expressed 
on the cell surface. Subsequently it is cleaved by the ac-
tion of  a metalloproteinase (TACE) and released into 
the extracellular medium as a soluble protein[62]. Often, 
TNF-α is not detected in high concentrations in serum or 
tissues, but increases intensively on various inflammatory 
and infectious conditions. Two receptors, TNF-R1 (TNF 
receptor type 1; CD120a; p55/60) and TNF-R2 (TNF 
receptor type 2; CD120b; p75/80) bind to membrane-
integrated TNF (memTNF) as well as soluble TNF-α 
(sTNF-α). In the vast majority of  cells, TNF-R1 appears 
to be the key mediator of  TNF-α signaling, whereas in 
the lymphoid system, TNF-R2 seems to play a major role. 
Low TNF-α secretion by blood mononuclear cells may 
be related to ReA development since TNF-α deficiency 
may interfere with eradication of  bacterial infection in 
its early stages[34,63-66]. However, other studies suggest that 
TNF-α could have a pathogenic role during the chronic 
stage of  ReA in line with the role of  this cytokine in RA. 
In this regard, some studies have revealed significant in-
crease of  TNF-α production in chronic ReA compared 
with acute ReA[66]. These data support the possibility that 
anti-TNF-α treatment in ReA during the chronic phase 
of  the disease could be beneficial. However, considering 
that TNF-α may be required for the elimination of  ReA-
associated bacteria, anti-TNF-α biologics might favor bac-
teria growth. Results obtained in our laboratory showed 
that TNFRp55 deficiency favors the development of  ReA 
after infection with Y. enterocolitica[14]. These data support 
the idea that the relative lack of  TNF-α may play a pro-
tective role in ReA at acute phase of  disease. On the other 
hand, we have demonstrated an in vivo regulatory role for 
TNFRp55 signaling in fine-tuning of  Th17 and Th1 pro-
grams during bacterial-induced ReA through modulation 
of  the common p40 subunit of  IL-23 and IL-12[15]. This 
evidence suggests that TNF-α might have a dual role in 
ReA, playing a protective role first and during the initial 
stage. However, during the chronic stage of  the disease, 
TNF-α would act as a pro-inflammatory cytokine. 
IFN-γ
IFN-γ is produced mainly by natural killer (NK) cells 
and a particular subset of  T cells, namely Th1 cells[67]. As 
previously mentioned, IL-12 is the main stimulator of  
IFN-γ production[47,50]. Thus, IL-12 and IFN-γ coordinate 
the link between pathogen recognition by innate immune 
cells and the induction of  specific immunity by mediat-
ing a positive feedback loop to amplify the Th1 response. 
The functional IFN-receptor (IFN-R) consists of  2 
ligand-binding IFNGR1 chains and 2 signal-transducing 
IFNGR2 chains[68]. Mice deficient in IFN-γ or its receptor 
are susceptible to an array of  intracellular pathogens[69-71]. 
It was thought that Th1 cells cause damage in the joints 
mainly through IFN-γ driven inflammatory mechanisms. 
However, similar to TNF-α, conflicting data have been 
reported about the role of  IFN-γ in ReA. As previously 
mentioned, some authors have reported an aberrant 
lower production of  IFN-γ in patients with ReA[28-34,52]. In 
contrast, in patients with C. trachomatis-induced ReA, the 
synovial fluid concentrations of  IFN-γ were significantly 
higher than in OA patients but no significant differences 
were found between ReA and RA patients[45]. Similar re-
sults were reported by Singh et al[41]. Other studies have 
shown that the percentages of  IFN-γ positive CD3+ cells 
were significantly higher in peripheral blood and synovial 
fluid of  chronic ReA patients[66]. These data support the 
idea that, as with TNF-α, IFN-γ may play a significant 
protective role in ReA in the acute phase of  disease. 
However, in the chronic phase, this cytokine, as in RA, 
could play a pathogenic role in ReA.
IL-10
IL-10 is an anti-inflammatory cytokine with a major role 
in preventing inflammatory and autoimmune patholo-
gies[72]. Based on a large body of  evidence, T cells are 
thought to be the main source of  IL-10 in vivo. Regulatory 
T (Treg) subsets are also a key source of  IL-10 in vivo and 
play a central role in mediating the inflammation con-
trol. However, it is now accepted that IL-10 is expressed 
by subsets of  all CD4+ T helper populations, including 
Th1, Th2 and Th17[73]. Nevertheless, this cytokine is also 
expressed by B cells and cells of  the innate immune sys-
tem (DCs, stimulated macrophages, mast cells, NK cells, 
eosinophils and neutrophils)[74]. This cytokine binds to 
IL-10 receptor (IL-10R), which consists of  two subunits. 
They are members of  the interferon receptor family and 
belong to JAK/STAT3 class of  receptors[74]. Extensive 
studies have demonstrated that IL-10 inhibits the produc-
tion of  pro-inflammatory cytokines and chemokines in 
activated monocytes/macrophages and inhibits prolifera-
tion of  CD4+ T cells[75]. However, the role of  IL-10 in 
ReA is less clear. Appel et al[32] reported that the amount 
of  IL-10 and TGF-β secreting cells was higher in ReA 
than in RA patients. This result was accompanied by a 
lower level of  TNF-α secretion in ReA patients. Interest-
Eliçabe RJ et al . Cytokines and reactive arthritis
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ingly, all ReA patients had a disease course of  less than 6 
mo. These authors suggest that this cytokine milieu might 
contribute to the lack of  elimination of  the triggering 
agent. Similar results were reported by Yin et al[28]. These 
authors found that synovial fluid mononuclear cells 
secreted low amounts of  IFN-γ and TNF-α, but high 
amounts of  IL-10 upon stimulation with specific bacte-
ria, which was responsible for the suppression of  IFN-γ 
and TNF-α[28]. There is also evidence indicating associa-
tion of  the IL-10 promoter region with the development 
of  ReA. This raises the possibility that high levels of  
IL-10 in the joints of  patients with ReA may be geneti-
cally determined, making these individuals more prone to 
the persistence of  arthritogenic bacteria[76].
Despite these clinical findings suggesting a pathogenic 
role of  IL-10 in human ReA, IL-10 depletion and IL-10 
treatment in other types of  arthritis models have dem-
onstrated the anti-inflammatory properties of  IL-10 in 
arthritis[77-80]. Results obtained in our laboratory showed 
that the number of  Treg cells as well as the FoxP3 mRNA 
expression and IL-10 levels were significantly decreased 
in joint regional lymph nodes of  TNFRp55-/- mice at the 
arthritis onset[81]. These results would indicate that IL-10 
plays a protective role during the acute phase of  arthritis. 
However, the clinical evidence suggests that high levels 
of  IL-10 could promote bacterial persistence, favoring 
the development of  ReA.
TREATMENT BASED ON BIOLOGICAL 
AGENTS
IL-6 antagonists
Published data on the effects of  IL-6 blockade in pa-
tients with SpA are very scarce. Thus, in 1996 a report 
describes a patient with ReA who received a murine anti-
IL-6 antibody[82] and, in 2009, tocilizumab was reported 
to be successful in another patient with ReA[83]. Only two 
injections of  tocilizumab led to complete clinical remis-
sion from symptoms caused by ReA[83]. Recently, Kwan 
et al[84] reported successful results of  tocilizumab in the 
treatment of  a case of  ReA precipitated by intravesical 
bacillus Galmette-Guèrin (BCG) which did not respond 
completely to disease modifying antirheumatic drugs 
(DMARDs). As previously mentioned, IL-6 is one of  the 
cytokines that favor the differentiation of  naïve T cells 
into Th17 cells[39]. Therefore, it is possible that the inhibi-
tory action of  tocilizumab is exerted indirectly interfering 
with the differentiation of  Th17 cells. These data indicate 
that IL-6 may play a pivotal role directly or indirectly in 
the pathogenesis of  ReA and tocilizumab treatment can 




































Figure 1  The role of cytokines in reactive arthritis depending on the state of disease. Arthritogenic bacteria enter through the gastrointestinal or genitourinary 
mucosa using different strategies (M cells; epithelial cells) and induce an inflammatory response. During the acute stage, interleukin (IL)-12 and IL-23 plus IL-6 pro-
mote the development of Th1 and Th17 cells, respectively. These cells are a major source of interferon (IFN)-γ and IL-17, favoring the bacterial clearance. The IFN-γ 
activates macrophages to kill phagocyted bacteria and secrete tumor necrosis factor (TNF)-α. IL-17 induces the migration of polymorphonuclear cells to the site of 
infection. However, this effect could be disrupted by the action of regulatory T cells producing IL-10. This regulatory event contributes to the bacterial persistence in 
the mucosa. Then, the bacteria could reach the joint transported by macrophages. In chronic stages, IL-6, TNF-α, IFN-γ and IL-17 exert pro-inflammatory roles in the 
joint. These cytokines stimulate articular cells (e.g., fibroblasts, osteoblast) and immune cells to produce more cytokines and pro-inflammatory mediators that contrib-
ute to chronic articular inflammation. These effects may be enhanced by the presence of bacteria or bacterial antigens in the joint. EC: Epithelial cell; MC: M cell; MO: 
Macrophage; PMN: Polymorphonuclear cell; DC: Dendritic cell.
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TNF-antagonists
The pathogenic role during the critical stage of  the dis-
ease supports the idea that TNF-α blocking agents could 
be an effective treatment for patients with ReA who 
develop severe arthritis that does not respond to conven-
tional lines of  treatment. Thus, Kaipiainen-Seppönen et 
al[85] reported two cases of  ReA post Y. enterocolitica treat-
ed early with infliximab (an anti-TNF-α antibody). One 
patient that received this treatment within 2 mo after the 
disease onset exhibited an improvement after the third 
infusion. The second patient that was treated after one 
month of  evolution showed an immediate clinical im-
provement with almost complete regression after 15 d[85]. 
Recently, Thomas-Pohl et al[86] obtained the same result 
in one patient with ReA triggered by a gastrointestinal 
infection. Similar results were reported by Edrees in a pa-
tient with a severe case of  C. trachomatis-related ReA that 
was successfully treated with etanercept (a fusion protein 
of  TNFRp75)[87]. Thus, anti-TNF-α therapy has proved 
efficacious in some cases. However, sufficient data are 
lacking and theoretical concerns with their use remain. 
Large controlled trials are needed to evaluate the role of  
TNF-α blocking agents in ReA. 
CONCLUSION
The network of  cytokines is complex with feedback 
regulatory circuits that make it difficult to elucidate the 
role of  a particular cytokine in ReA. In addition, the clini-
cal reports of  cytokine levels in patients with ReA have 
included patients in different stages of  the disease or 
they are not large enough to support the role of  differ-
ent cytokines in ReA development. However, the current 
evidence in patients with anti-cytokine treatments sug-
gests that IL-6 and TNF-α may play central roles in ReA 
pathogenesis. Furthermore, the IL-17/23 axis should be 
considered in the picture of  ReA development, although 
further investigations are necessary for these cytokines. 
According to the presented evidence in this review, Fig-
ure 1 shows the different functions of  the cytokines in 
ReA depending on the disease phases. Moreover, animal 
models may contribute to provide insight into the im-
munopathogenic mechanisms mediated by a particular 
cytokine in ReA and to support anti-cytokine treatments.
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